Hypothesis

Timed administration of NMN during the early refeeding phase after a fasting‑mimicking diet (FMD) will produce a synergistic increase in SIRT1 deacetylase activity that exceeds the effect of either intervention alone.

Rationale

• Fasting/FMD upregulates SIRT1 expression 2‑8‑fold in preclinical models and increases SIRT1/FOXO1 mRNA in humans taking fasting‑mimetic supplements【3】【4】.
• Fasting also elevates NAD+ turnover via CD38 and PARP, creating a high‑demand state for NAD+ that can be met by precursor supplementation.
• NMN or NR reliably doubles circulating NAD+ within 14 days【1】【2】, but NAD+ elevation alone does not guarantee SIRT1 activation because enzyme activity depends on both substrate availability and enzyme abundance.
• Therefore, delivering NMN when SIRT1 expression is peaking (early refeeding) should maximize the fraction of NAD+ that is channeled into SIRT1 catalysis.

Novel Mechanistic Insight

We propose that the fasting‑induced rise in NAD+‑consuming enzymes (e.g., PARP1 activated by mild DNA damage during fasting) creates a transient NAD+ sink. When NMN is supplied during refeeding, the newly synthesized NAD+ preferentially fuels SIRT1 rather than being dissipated by PARP/CD38, because SIRT1’s affinity for NAD+ (Km ~50‑100 µM) is lower than that of CD38 (Km ~130 µM) and PARP (Km ~20‑50 µM) under the altered redox state. This substrate‑enzyme matching hypothesis predicts a greater increase in the SIRT1‑mediated deacetylation of FOXO1 and p53 in peripheral blood mononuclear cells (PBMCs) when NMN is given in the fasting‑refeeding window.

Testable Prediction

In a randomized, crossover trial of adults aged 60‑75, three 4‑week periods will be compared:

1. NMN alone – 250 mg NMN twice daily continuously.
2. FMD alone – 5‑day low‑calorie, plant‑based diet once per month.
3. NMN + FMD (timed) – same FMD plus NMN 250 mg twice daily only on days 1‑3 of refeeding after each FMD cycle.

Primary outcome: ex vivo SIRT1 activity measured as FOXO1 deacetylation rate in isolated PBMCs at the end of each period. Secondary outcomes: whole‑blood NAD+ levels, SIRT1 mRNA expression, and markers of inflammation (IL‑6, TNF‑α).

Falsifiability

If the timed NMN + FMD condition does not produce a statistically significant greater increase in SIRT1 activity (≥15 % over NMN alone or FMD alone, p < 0.05), the hypothesis is falsified. Conversely, a significant synergistic increase would support the mechanistic model that fasting creates a high‑demand NAD+ state that directs precursor‑derived NAD+ toward SIRT1 catalysis.

References

[1] https://renuebyscience.com/pages/a-current-list-of-completed-nmn-human-trials [2] https://www.nmn.com/news/scientists-unveil-results-from-human-trial-directly-comparing-three-nad-precursors [3] https://pubmed.ncbi.nlm.nih.gov/33770194/ [4] https://ffhdj.com/index.php/ffhd/article/view/752